TNFRSF17 and AL amyloidosis: Idecaptagene-vicleucel (bb2121) is an anti-BCMA chimeric antigen receptor T-cell therapy for the treatment of multiple myeloma, approved by the FDA in 2021 for the treatment of adults with relapsed or refractory multiple myeloma, who have received at least three lines of anti-CD38/PI/IMID treatment.